18F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung Cancer
关键词
抽象
日期
| 最后验证: | 12/31/2019 |
| 首次提交: | 12/08/2014 |
| 提交的预估入学人数: | 03/01/2016 |
| 首次发布: | 03/07/2016 |
| 上次提交的更新: | 01/23/2020 |
| 最近更新发布: | 01/26/2020 |
| 实际学习开始日期: | 11/30/2014 |
| 预计主要完成日期: | 11/30/2020 |
| 预计完成日期: | 11/30/2020 |
状况或疾病
干预/治疗
Biological: 18-F-FAZA Scan
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Experimental: 18-F-FAZA Scan All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction | Biological: 18-F-FAZA Scan All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction |
资格标准
| 有资格学习的年龄 | 18 Years 至 18 Years |
| 有资格学习的性别 | All |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: 1. Age ≥ 18 years 2. Patients with stage II or III lung cancer (both NSCLC and SCLC) qualifying for radiotherapy to the primary tumor, with or without treatment of mediastinal or hilar lymph nodes 3. Intention to treat using radiotherapy according to the current treatment policies of the PMH Lung Group 4. Concurrent systemic therapy allowed 5. A negative serum pregnancy test within the two week interval immediately prior to PET-CT imaging, in women of child-bearing age 6. Ability to provide written informed consent to participate in the study Exclusion Criteria: 1. Previous radiotherapy to intended treatment volumes. 2. Previous systemic therapy 3. Active malignancy other than lung cancer 4. Unable to remain supine for more than 60 minutes 5. Pregnancy 6. Age less than 18 years old 7. Failure to provide written informed consent |
结果
主要结果指标
1. Number of patients with lung cancer using the PET tracer FAZA to image primary tumor hypoxia prior to treatment with radiotherapy [5 years]
2. Number of patients with lung cancer using 4D (gated) and static PET imaging of FAZA uptake [5 years]
次要成果指标
1. Proportion of the volume of injected FAZA tracer taken up in the tumor prior to treatment with radiotherapy [5 years]
